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Abstract
The conversion of 5-aminoimidazole ribonucleotide (AIR) to 4-carboxy-AIR
(CAIR) represents an unusual divergence in purine biosynthesis: microbes
and nonmetazoan eukaryotes use class I PurEs while animals use class II
PurEs. Class I PurEs are therefore a potential antimicrobial target; however, no enzyme activity assay is suitable for high throughput screening
(HTS). Here we report a simple chemical quench that fixes the PurE substrate/product ratio for 24 h, as assessed by the Bratton-Marshall assay
(BMA) for diazotizable amines. The ZnSO4 stopping reagent is proposed to
chelate CAIR, enabling delayed analysis of this acid-labile product by BMA
or other HTS methods.
Keywords: purine biosynthesis, aminoimidazole, substrate depletion,
chelation
De novo purine biosynthesis harbors an unusual divergence in a ubiq-
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uitous biosynthetic pathway [1]. In most microbes and nonmetazoan eu-

3

karyotes, a class I PurE [PurE1, N 5 -carboxyaminoimidazole ribonucleotide

4

(NCAIR) mutase, EC 5.4.99.18] reversibly converts NCAIR to 4-carboxy-5-

5

aminoimidazole ribonucleotide (CAIR) (Fig. 1) [2]. Animals produce CAIR

6

by a different route, using a class II PurE (PurE2, 5-aminoimidazole ribonu-

7

cleotide (AIR) carboxylase, EC 4.1.1.21) [3, 4, 5]. Microbial pathogenesis

8

relies upon purine biosynthesis [6], particularly purE1, which is therefore a

9

promising but unexploited antibiotic target [7, 8]. Inhibitors selective for

10

PurE1 could have antibacterial, antifungal, or herbicidal activity [9]. In this

11

work, we describe a functional assay for PurE that is compatible with in-

12

hibitor identification by high-throughput screening (HTS) methods.

13

Currently available PurE functional assays are not amenable to HTS

14

methods. A continuous ultraviolet (UV) assay that monitors the absorbance

15

decrease due to CAIR decarboxylation [10, 11, 2] is subject to spectral in-

16

terference by many candidate inhibitors. CAIR synthesis assays are compli-

17

cated by the acid lability of the NCAIR substrate [12, 13, 2], the need for

18

multiple coupling enzymes [14, 9], and, for discontinuous assays detecting in-

19

organic phosphate production, handling of malachite green reagent [15] and

20

a background due to formation of phosphate by the coupling enzymes. The

21

Bratton-Marshall assay (BMA) [16] was used in early studies of PurE2 [3],

22

but seldom thereafter. The BMA yields intensely colored AIR and CAIR

23

derivatives, AIR-BM and CAIR-BM (Fig. 1), that possess characteristic vis-

24

ible absorbance spectra [17], are relatively stable, and might be suitable for

25

HTS methods. The BMA, however, requires multiple timed reagent additions

26

that would be difficult to implement during parallel screens. An alternative

2

27

would be to stop the PurE reaction prior to BMA workup using a reagent

28

that does not alter product yields.

29

The first task was to determine an extinction coefficient for CAIR-BM at

30

500 nm, a goal that requires pure CAIR. A new CAIR synthesis, which uses

31

LiOH to saponify aminoimidazole-4-carboxamide ribonucleotide (AICAR)

32

[18] and thereby facilitates salt removal (see Experimental Procedures in the

33

Supplementary material), furnished CAIR in high yield (85%) and purity

34

(99%). No signal corresponding to AIR H2 was observed in 1 H NMR spectra

35

(Fig. S1 in the Supplementary material). Mass spectrometry (MS) analy-

36

sis of BMA reaction mixtures revealed only the expected molecular ions for

37

single BM adducts and ions present in control mixtures (Table S1 in the Sup-

38

plementary material). HPLC analysis of CAIR subjected to BMA workup

39

showed 97% CAIR-BM / 3% AIR-BM (Fig. S2 in the Supplementary mate-

40

rial); a small amount of AIR evidently forms during the BMA acid quench

41

step. CAIR-BM appears to consist of a mixture of species that cannot be

42

resolved by HPLC but that possess the same molecular formula. An isobaric

43

mixture might also account for the complex shape of the CAIR-BM visible

44

spectrum (Fig. S3 in the Supplementary material). Aliquots of a solution

45

containing pure CAIR were (1) used to determine an accurate CAIR concen-

46

tration, by complete enzymatic conversion to AIR followed by BMA analysis,

47

and (2) used to obtain a spectrum of CAIR-BM, which gave CAIR-BM
= 11 200
500

48

M−1 cm−1 (for comparison, AIR-BM
= 24 800 M−1 cm−1 [17]).
500

49

The second task was to identify an enzyme quenching method that is

50

compatible with BMA workup and product analysis. CAIR and analogues

51

form stable complexes in which aminoimidazole N3 and O7 atoms (Fig. 1)

3

52

coordinate a transition metal ion [19]. (CAIR)n -metal (n = 2 or 3) complexes

53

(Fig. S4 in the Supplementary material) do not bind to or inhibit chicken

54

PurE2 in the presence of excess free CAIR [20, 21, 22]. Mg2+ inhibits PurE2-

55

mediated CAIR decarboxylation but not AIR carboxylation, consistent with

56

the formation of a low-affinity metal-CAIR complex [10, 4]. To determine if

57

transition metals can rapidly and reversibly form CAIR-metal complexes, a

58

ten-fold molar excess (relative to the initial CAIR concentration) of NiSO4 or

59

ZnSO4 was added to UV-monitored CAIR decarboxylation reaction mixtures.

60

CAIR decarboxylation stopped immediately, but could be restarted by the

61

addition of EDTA (Fig. S5 in the Supplementary material). EDTA had no

62

effect on BMA workup; the initial acidification step apparently dissociates

63

CAIR complexes formed with either Ni2+ or Zn2+ .

64

Zn2+ appeared to form a CAIR complex with higher kinetic stability than

65

Ni2+ , and to pose fewer concerns with regard to toxicity, spectral overlap

66

with (C)AIR-BM, and redox chemistry. A CAIR decarboxylation reaction

67

mixture incubated at 30 ◦ C was stopped at ∼30% completion by the addition

68

of ∼3 molar equivalents of ZnSO4 (Fig. 2). Equivalent yields of CAIR-BM

69

were obtained if the BMA workup was delayed by up to 4 h. In contrast,

70

Ni2+ -stopped reactions lost CAIR at the rate of about 10% per h at 30

71

◦

C (data not shown). A saturation curve employing ZnSO4 quenching gave

72

kinetic constants similar to the standard continuous UV assay (Fig. S6 in

73

the Supplementary material). Indistinguishable velocities were obtained at

74

40 µM CAIR for a quenched reaction worked up promptly or after a 24 h

75

delay. Therefore ZnSO4 is a suitable stopping reagent for PurE reaction

76

mixtures.

4

77

Metal stopping reagents are proposed to work by rapid substrate de-

78

pletion, an uncommon mode of enzyme inhibition (e.g., vancomycin [24])

79

[25]. Immobilized metal affinity chromatography (IMAC) was used to test if

80

CAIR binds to Ni2+ , immobilized on a nitrilotriacetic acid (NTA) column.

81

An equimolar mixture of CAIR and AIR was applied to the NiNTA column.

82

The first column fraction contained pure AIR, consistent with selective re-

83

tention of CAIR on the column as a CAIR-Ni2+ complex (Figs. S7 and S8 in

84

the Supplementary material). Subsequent fractions contained CAIR, indicat-

85

ing that the Ni2+ -CAIR interaction was reversible (data not shown). While

86

these results do not exclude the possibility that PurE is inhibited by direct

87

protein-metal interactions, they indicate that the rapid formation of a stable

88

CAIR-transition metal complex is sufficient to account for ZnSO4 -mediated

89

arrest of CAIR decarboxylation.

90

In summary, we have identified a PurE reaction quencher that facilitates

91

HTS using the BMA as a detection method. PurE-mediated CAIR decar-

92

boxylation stopped by a single liquid addition, of a ZnSO4 solution, allows

93

delayed BMA workup. The BMA is compatible with candidate inhibitors

94

that absorb UV light, a common practical concern for detecting initial hits,

95

which often have low potency and therefore require high compound concen-

96

trations that cause significant spectral interference. BMA-detected PurE

97

screens require no other enzymes and can be used to screen candidate in-

98

hibitors that do not contain diazotizable amines or strong metal chelators.

99

The metal stopping reagent could be adapted for use with other detection

100

methods or in assays of 5-aminoimidazole-4-N -succinylcarboxamide ribonu-

101

cleotide (SAICAR) synthetase (PurC, EC 6.3.2.6), the other enzyme known

5

102

to use CAIR as a substrate. SAICAR has recently been shown to activate

103

cancer metabolism via pyruvate kinase isoform M2 [26].

104
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Figure Captions

215

Figure 1: PurE1 reaction and CAIR/AIR detection by Bratton-Marshall

216

assay (BMA). NCAIR decarboxylates to AIR (half-life of 0.9 min at pH 7.8

217

and 30 ◦ C) during the enzyme assay [2], an acid-dependent process that goes

218

to completion during the BMA. R5P = ribosyl 50 -phosphate, R = H (AIR-

219

BM) or COO− (CAIR-BM). CAIR aminoimidazole atoms are numbered as

220

in PDB residue type C2R. CAIR atoms proposed to coordinate transition

221

metals are indicated with unfilled arrows.

222

Figure 2: Zn2+ ions stop CAIR decarboxylation. Reaction mixtures (1.26

223

mL final volume) at 30 ◦ C contained 50 mM Tris•HCl, pH 8.0, 42 µM CAIR,

224

and 0.13 µg Acetobacter aceti PurE1 (0.005 units) [23]. At 5 min, ZnSO4

225

(0.1 mM) was added to one reaction. Aliquots (0.2 mL) were removed prior

226

to the addition of enzyme (zero time point) and at indicated intervals, and

227

immediately added to a 1.7 mL centrifuge tube containing a freshly prepared

228

mixture of 20% (w/v) trichloroacetic acid / 1.33 M potassium phosphate,

229

pH 1.4, (0.1 mL) and 0.1% (w/v) sodium nitrite (0.1 mL). After 3 min, 0.5%

230

(w/v) ammonium sulfamate (0.1 mL) was added to destroy excess nitrite.

231

After an additional min, Bratton-Marshall reagent [0.1 mL of 0.1% (w/v)

232

N -(1-naphthyl)ethylenediamine dihydrochloride] was added. After 10 min,

233

the solution (0.6 mL) was centrifuged (16 000g, 30 s) to eliminate bubbles

234

and the absorbance at 500 nm (A500 ) was recorded.

235

CAIR consumption was quantitated using a differential extinction coef-

236

ficient for CAIR to AIR conversion, ∆500 = AIR-BM
− CAIR-BM
= 13 600 ±
500
500

237

1600 M−1 cm−1 . [CAIR] values at time t were determined using (AAIR-BM
−
500

11

238

At500 )/∆500 , where AAIR-BM
was from a control reaction in which CAIR was
500

239

completely converted to AIR.

240

The symbols and error bars represent the mean and standard deviation,

241

respectively, for at least three independent replicates of ZnSO4 -quenched

242

(filled circles) and -unquenched control (open circles) reactions. Concentra-

243

tions determined at t > 5 min were significantly different in quenched and

244

control reaction mixtures [one-tailed t-test, P -value < 0.01 (**) or < 0.001

245

(***)]. The slope of the line connecting the first two points corresponds to

246

0.003 units of enzyme activity, comparable to the 0.004 units expected under

247

the reaction conditions [23].
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